Ventyx Biosciences, Inc.
NASDAQ:VTYX
2.15 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Ventyx Biosciences, Inc. |
Symbool | VTYX |
Munteenheid | USD |
Prijs | 2.15 |
Beurswaarde | 151,938,630 |
Dividendpercentage | 0% |
52-weken bereik | 1.79 - 15.805 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Raju S. Mohan Ph.D. |
Website | https://www.ventyxbio.com |
An error occurred while fetching data.
Over Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)